A weight loss drug available over the counter in the UK could help women with treatment-resistant ovarian cancer respond to chemotherapy again, a new study suggests.

NICE has announced today, its decision not to recommend olaparib for women with advanced ovarian cancer who had previously responded to platinum chemotherapy for six months or longer.

Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.